NCT01660360 is a Phase 1 clinical trial of Tanibirumab in Advanced Cancer, sponsored by PharmAbcine.

Who is sponsoring NCT01660360?

NCT01660360 is sponsored by PharmAbcine.

What drugs are being tested in NCT01660360?

Interventions in NCT01660360: Tanibirumab.

What condition does NCT01660360 study?

NCT01660360 studies Advanced Cancer, Metastatic Cancer.

Is NCT01660360 still recruiting?

NCT01660360 is currently completed. Last updated 27 January 2014.

Last reviewed 2014-01-27 · How we verify

NCT01660360

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of the Safety and Pharmacokinetics of a Fully Human Monoclonal Antibody to the Vascular Endothelial Growth Factor Receptor2 (Tanibirumab) in Patients With Advanced Cancers or Metastatic Cancer

Completed Phase 1 Last updated 27 January 2014

What this trial tests

Phase 1 trial testing Tanibirumab in Advanced Cancer in 26 participants. Completed in 1 September 2013.

Timeline

1 November 2011

Primary endpoint
1 September 2013

1 September 2013

Quick facts

Lead sponsor	PharmAbcine
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	1 November 2011
Primary completion	1 September 2013
Estimated completion	1 September 2013
Sites	1 location across South Korea

Drugs / interventions tested

Tanibirumab — full drug profile →

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →
Metastatic Cancer — all drugs for Metastatic Cancer →

Sponsor

PharmAbcine — full company profile →

Who can join

20 and older, any sex, with Advanced Cancer or Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety and tolerability
Time frame: 28days
The safety and tolerability of Tanibirumab will be assessed using the following measures: frequency and nature of dose-limiting toxicities (DLTs); nature, severity, and relatedness of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, v4.0; changes in vital signs; and changes in clinical laboratory parameters.

Sponsor's own description

The primary objective of this study is to assess the safety, tolerability, and maximum tolerated dose (MTD) of Tanibirumab in patients with advanced or metastatic cancer who are refractory or for whom there are no standard therapeutic option. * To evaluate the pharmacokinetics of Tanibirumab in such patients * To determine a recommended phase II dose (RP2D) of Tanibirumab based on above assessments

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comprehensive review of targeted therapy for colorectal cancer.
Xie YH, Chen YX, Fang JY. · · 2020 · cited 1162× · PMID 32296018 · DOI 10.1038/s41392-020-0116-z

Verify or expand the search:

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Other PharmAbcine trials

Trials by the same sponsor.

NCT05957081 — Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 · Phase 1 · recruiting
NCT05953012 — Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration · Phase 1 · completed
NCT04986852 — Olinvacimab With Pembrolizumab in Patients With mTNBC · Phase 2 · terminated
NCT03856099 — TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab · Phase 2 · terminated
NCT03722342 — TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01660360 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PharmAbcine
Last refreshed: 27 January 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01660360.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing